Figure 1 A



Cycle 1 (21 days)
Mo Tu We Th Fr Sa Su Mo Tu We Th Fr Sa Su Mo Tu We Th Fr Sa Su Mo Tu We Th Fr
End of DLT evaluation period
D21
D8;D9
D1*;D2
SO-C101

Figure 1 B



Cycle 1 (21 days)
Mo Tu We Th Fr Sa Su Mo Tu We Th Fr Sa Su Mo Tu We Th Fr Sa Su Mo Tu We Th Fr
End of DLT evaluation period
D21
D1*;D2
D8;D9
SO-C101
pembrolizumab



Figure 2

Figure 2 E



14 Oct
23 Sep
02 Sep
03 Jul
03 Jun
14 Jan
15 Dec
25 Nov
SO-C101
SO-C101 + pembrolizumab

Figure 2




Figure 3




Figure 4




Figure 5




Figure 6



1 cycle
x repeated at least once
x days
y days
z days
Daily dose
Dose levels
increase 20-100%
0
A
B
C
D
E
initial
increased

Figure 7




before treatment (C1D1)
after treatment (C1D6)
A
SO-C101 monotherapy
SO-C101 +Pembro
% Ki-67+ CD8+ T cells
SO-C101 dose level (µg/mL)
B
SO-C101 monotherapy
SO-C101 +Pembro
% Ki-67+ NK cells
SO-C101 dose level (µg/mL)

Figure 8


before treatment
after treatment (C2D15)
A CD3+ T cell density in tumor
SO-C101 monotherapy
SO-C101+Pembro
CD3+T cell density (cells/mm2)
2000
1000
400
200
0
0.75
1.5
3
6
9
15
1.5
3
SO-C101 dose level (µg/mL)
B CD8+ T cell density in tumor
SO-C101 monotherapy
SO-C101+Pembro
CD8+ T cell density (cells/mm2)
2000
1000
500
250
0
0.75
1.5
3
6
9
15
1.5
3
SO-C101 dose level (µg/mL)

C CD8+ T cell/Treg ratio in tumor





Figure 9


A
B
C
gene expression score
SCR
TREAT
SO-C101
SO-C101 + pembrolizumab